UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2019
INMUNE BIO INC. |
(Exact name of registrant as specified in charter) |
Nevada |
| 001-38793 |
| 47-5205835 |
(State or other jurisdiction |
| (Commission |
| (IRS Employer |
of incorporation) |
| File Number) |
| Identification No.) |
1224 Prospect Street, Suite 150, La Jolla, CA 92037
(Address of Principal Executive Offices) (Zip Code)
(858) 964 3720
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock | IMNB | NASDAQ |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure
On June 4, 2019, INmune Bio, Inc. (the “Company”) issued a press release (the “Release”) announcing that its Director of Neuroscience, CJ Barnum, Ph.D. will conduct a presentation regarding the Company’s Alzheimer’s drug candidate XPro1595 at the TNF Conference on June 4, 2019.
A copy of the Release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Exhibits 99.1 shall not be deemed “filed” for purposed of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
Exhibit Number |
| Description |
| INmune Bio to present Alzheimer’s Drug Candidate XPro1595 at The TNF Conference on June 4, 2019 |
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INMUNE BIO INC. | ||
| |||
Date: June 6, 2019 | By: | /s/ David Moss | |
| David Moss | ||
| Chief Financial Officer | ||
| 3 |
EXHIBIT 99.1
INmune Bio to present Alzheimer’s Drug Candidate XPro1595 at The TNF Conference
La Jolla, CA – June 4, 2019 – INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that CJ Barnum, Ph.D., Director of Neuroscience, will be presenting a poster and giving a scientific talk on Alzheimer’s drug candidate XPro1595 at the TNF Conference on June 4, 2019.
The poster presentation and talk, titled “A Phase 1b biomarker-directed study to target soluble tumor necrosis factor in Alzheimer’s (AD) patients”, will discuss INmune Bio’s clinical approach to treating Alzheimer’s disease.
“XPro1595 has been represented at the TNF Conference for more than a decade. I am often told that the support and feedback provided by TNF experts at this conference has gone a long way in shaping the enormous dataset that we enjoy with XPro1595. I am very excited to share how these efforts have paid off and that we are days away from enrolling the first patient in our Alzheimer’s disease trial,” says Dr. CJ Barnum.
The TNF Conference brings industry and academics together to share ideas and research on tumor necrosis factor (TNF), the target of XPro1595.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit Junewww.inmunebio.com.
INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com
Media Contact:
Antenna Group
Sharon Golubchik
(201) 465-8008
INmuneBio@AntennaGroup.com
Investor Contact:
KCSA Strategic Communications
Valter Pinto / Scott Eckstein
PH: (212) 896-1254 / (212) 896-1210INmune@KCSA.com